515 related articles for article (PubMed ID: 31013716)
1. A Rich Array of Prostate Cancer Molecular Biomarkers: Opportunities and Challenges.
Kohaar I; Petrovics G; Srivastava S
Int J Mol Sci; 2019 Apr; 20(8):. PubMed ID: 31013716
[TBL] [Abstract][Full Text] [Related]
2. Are localized prostate cancer biomarkers useful in the clinical practice?
Carneiro A; Priante Kayano P; Gomes Barbosa ÁR; Langer Wroclawski M; Ko Chen C; Cavlini GC; Reche GJ; Sanchez-Salas R; Tobias-Machado M; Sowalsky AG; Bianco B
Tumour Biol; 2018 Sep; 40(9):1010428318799255. PubMed ID: 30204063
[TBL] [Abstract][Full Text] [Related]
3. Genomic Markers in Prostate Cancer Decision Making.
Cucchiara V; Cooperberg MR; Dall'Era M; Lin DW; Montorsi F; Schalken JA; Evans CP
Eur Urol; 2018 Apr; 73(4):572-582. PubMed ID: 29129398
[TBL] [Abstract][Full Text] [Related]
4. Blood-based and urinary prostate cancer biomarkers: a review and comparison of novel biomarkers for detection and treatment decisions.
Hendriks RJ; van Oort IM; Schalken JA
Prostate Cancer Prostatic Dis; 2017 Mar; 20(1):12-19. PubMed ID: 27922627
[TBL] [Abstract][Full Text] [Related]
5. Biomarkers in prostate cancer - Current clinical utility and future perspectives.
Kretschmer A; Tilki D
Crit Rev Oncol Hematol; 2017 Dec; 120():180-193. PubMed ID: 29198331
[TBL] [Abstract][Full Text] [Related]
6. Prognostic Biomarkers Used for Localised Prostate Cancer Management: A Systematic Review.
Lamy PJ; Allory Y; Gauchez AS; Asselain B; Beuzeboc P; de Cremoux P; Fontugne J; Georges A; Hennequin C; Lehmann-Che J; Massard C; Millet I; Murez T; Schlageter MH; Rouvière O; Kassab-Chahmi D; Rozet F; Descotes JL; Rébillard X
Eur Urol Focus; 2018 Dec; 4(6):790-803. PubMed ID: 28753865
[TBL] [Abstract][Full Text] [Related]
7. Novel biomarkers and genomic tests in prostate cancer: a critical analysis.
Falzarano SM; Ferro M; Bollito E; Klein EA; Carrieri G; Magi-Galluzzi C
Minerva Urol Nefrol; 2015 Sep; 67(3):211-31. PubMed ID: 26054411
[TBL] [Abstract][Full Text] [Related]
8. An overview of current and emerging diagnostic, staging and prognostic markers for prostate cancer.
Brönimann S; Pradere B; Karakiewicz P; Abufaraj M; Briganti A; Shariat SF
Expert Rev Mol Diagn; 2020 Aug; 20(8):841-850. PubMed ID: 32552088
[TBL] [Abstract][Full Text] [Related]
9. Urine TMPRSS2:ERG Plus PCA3 for Individualized Prostate Cancer Risk Assessment.
Tomlins SA; Day JR; Lonigro RJ; Hovelson DH; Siddiqui J; Kunju LP; Dunn RL; Meyer S; Hodge P; Groskopf J; Wei JT; Chinnaiyan AM
Eur Urol; 2016 Jul; 70(1):45-53. PubMed ID: 25985884
[TBL] [Abstract][Full Text] [Related]
10. An overview of biomarkers in the diagnosis and management of prostate cancer.
Uhr A; Glick L; Gomella LG
Can J Urol; 2020 Aug; 27(S3):24-27. PubMed ID: 32875999
[TBL] [Abstract][Full Text] [Related]
11. New biomarkers for diagnosis and prognosis of localized prostate cancer.
Chistiakov DA; Myasoedova VA; Grechko AV; Melnichenko AA; Orekhov AN
Semin Cancer Biol; 2018 Oct; 52(Pt 1):9-16. PubMed ID: 29360504
[TBL] [Abstract][Full Text] [Related]
12. Recent progress and perspectives on prostate cancer biomarkers.
Hatakeyama S; Yoneyama T; Tobisawa Y; Ohyama C
Int J Clin Oncol; 2017 Apr; 22(2):214-221. PubMed ID: 27730440
[TBL] [Abstract][Full Text] [Related]
13. [Molecular biomarkers and prognostic factors for prostate cancer].
Kretschmer A; Tolkach Y; Ellinger J; Kristiansen G
Urologe A; 2017 Jul; 56(7):933-944. PubMed ID: 28573413
[TBL] [Abstract][Full Text] [Related]
14. Commercialized Blood-, Urinary- and Tissue-Based Biomarker Tests for Prostate Cancer Diagnosis and Prognosis.
Visser WCH; de Jong H; Melchers WJG; Mulders PFA; Schalken JA
Cancers (Basel); 2020 Dec; 12(12):. PubMed ID: 33339117
[TBL] [Abstract][Full Text] [Related]
15. Risk stratification of prostate cancer 2016.
Reiter RE
Scand J Clin Lab Invest Suppl; 2016; 245():S54-9. PubMed ID: 27533326
[TBL] [Abstract][Full Text] [Related]
16. Comparative assessment of urinary prostate cancer antigen 3 and TMPRSS2:ERG gene fusion with the serum [-2]proprostate-specific antigen-based prostate health index for detection of prostate cancer.
Stephan C; Jung K; Semjonow A; Schulze-Forster K; Cammann H; Hu X; Meyer HA; Bögemann M; Miller K; Friedersdorff F
Clin Chem; 2013 Jan; 59(1):280-8. PubMed ID: 23213079
[TBL] [Abstract][Full Text] [Related]
17. Diagnostic, prognostic and predictive value of cell-free miRNAs in prostate cancer: a systematic review.
Endzeliņš E; Melne V; Kalniņa Z; Lietuvietis V; Riekstiņa U; Llorente A; Linē A
Mol Cancer; 2016 May; 15(1):41. PubMed ID: 27189160
[TBL] [Abstract][Full Text] [Related]
18. Urinary biomarkers of prostate cancer.
Fujita K; Nonomura N
Int J Urol; 2018 Sep; 25(9):770-779. PubMed ID: 30129068
[TBL] [Abstract][Full Text] [Related]
19. Urinary biomarkers in prostate cancer detection and monitoring progression.
Wu D; Ni J; Beretov J; Cozzi P; Willcox M; Wasinger V; Walsh B; Graham P; Li Y
Crit Rev Oncol Hematol; 2017 Oct; 118():15-26. PubMed ID: 28917266
[TBL] [Abstract][Full Text] [Related]
20. Contemporary role of prostate cancer antigen 3 in the management of prostate cancer.
Auprich M; Bjartell A; Chun FK; de la Taille A; Freedland SJ; Haese A; Schalken J; Stenzl A; Tombal B; van der Poel H
Eur Urol; 2011 Nov; 60(5):1045-54. PubMed ID: 21871709
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
